点击图片查看原图
| Cat. Number |
C0154
|
| Chemical Name |
喜树碱，7-乙基-10-羟基（SN-38）,Camptothecin, 7-ethyl-10-hydroxy (SN-38)
|
| CAS Number |
86639-52-3
|
| Mol. Formula |
C22H20N2O5
|
| Mol. Weight |
392.40
|
| Qty 1 |
5mg
|
| Qty 2 |
10mg
|
| Appearance |
Light yellow crystallized powder
|
| Application Notes |
≥98%
|
| Synonym |
SN-38, 7-ethyl-10-hydroxy-CPT
|
| Melting Pt. |
228-235°C
|
| Storage condition |
-20°C
|
SN-38 is a camptothecin derivative. Camptothecin is a quinolone alkaloid precursor of irinotecan; it is originally found in Camptotheca. Camptothecin exhibits anticancer chemotherapeutic activity, inhibiting topoisomerase I and inducing double-stranded DNA breaks. Camptothecin is extremely cytotoxic and only its derivatives are clinically used as chemotherapeutics.
参考文献：
Rodríguez-Berna G, Mangas-Sanjuán V, Gonzalez-Alvarez M, et al. A promising camptothecin derivative: Semisynthesis, antitumor activity and intestinal permeability. Eur J Med Chem. 2014 Jun 25;83C:366-373. PMID: 24980118.
Berniak K, Rybak P, Bernas T, et al. Relationship between DNA damage response, initiated by camptothecin or oxidative stress, and DNA replication, analyzed by quantitative 3D image analysis. Cytometry A. 2013 Jul 11. [Epub ahead of print]. PMID: 23846844.
Redinbo MR, Stewart L, Kuhn P, et al. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science. 1998 Mar 6;279(5356):1504-13. PMID: 9488644.
Blackwood E, Epler J, Yen I, et al. Combination drug scheduling defines a “window of opportunity” for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900. Mol Cancer Ther. 2013 Oct;12(10):1968-1980. PMID: 23873850.
Walton MI, Eve PD, Hayes A, et al. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther. 2010 Jan;9(1):89-100. PMID: 20053762.